4.6 Review

Opioids for chronic pain management in patients with dialysis-dependent kidney failure

Journal

NATURE REVIEWS NEPHROLOGY
Volume 18, Issue 2, Pages 113-128

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41581-021-00484-6

Keywords

-

Funding

  1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the NIH [U01DK123787]
  2. NIDDK of the NIH [U01DK123813, U01DK123812A]
  3. Senior Advisor at NIDDK
  4. National Institute of Nursing Research of the NIH [K23NR018482]
  5. NIH
  6. Department of Health and Human Services

Ask authors/readers for more resources

Chronic pain is prevalent among patients with haemodialysis-dependent kidney failure, but its management is often inadequate. Opioid analgesics are commonly prescribed in these patients, but are associated with increased morbidity, mortality and healthcare resource use. Evidence for the effectiveness of opioids in pain management in this population is lacking.
Pain management in patients with haemodialysis-dependent kidney failure might involve the use of opioids. This Review discusses the safe implementation of opioid therapy in these patients, including specific pharmacological considerations, drug choice and opioid use monitoring. Chronic pain is highly prevalent among adults treated with maintenance haemodialysis (HD) and has profound negative effects. Over four decades, research has demonstrated that 50-80% of adult patients treated with HD report having pain. Half of patients with HD-dependent kidney failure (HDKF) have chronic moderate-to-severe pain, which is similar to the burden of pain in patients with cancer. However, pain management in patients with HDKF is often ineffective as most patients report that their pain is inadequately treated. Opioid analgesics are prescribed more frequently for patients receiving HD than for individuals in the general population with chronic pain, and are associated with increased morbidity, mortality and health-care resource use. Furthermore, current opioid prescribing patterns are frequently inconsistent with guideline-recommended care. Evidence for the effectiveness of opioids in pain management in general, and in patients with HDKF specifically, is lacking. Nonetheless, long-term opioid therapy has a role in the treatment of some patients when used selectively, carefully and combined with an ongoing assessment of risks and benefits. Here, we provide a comprehensive overview of the use of opioid therapy in patients with HDKF and chronic pain, including a discussion of buprenorphine, which has potential as an analgesic option for patients receiving HD owing to its unique pharmacological properties.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available